TargetMedia - Vioxx Statistics

Politics, Pain and the Torture of the American People

Monday, May 2, 2005, for immediate release

On April 15, 2005, the FDA posted a 22 page memorandum on the internet, titled "Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk". Atypically, the memorandum attracted limited attention.

The lengthy FDA document provides the first authorized and authoritative opinion on the issues and questions that were lingering since September 2004, on the cardiovascular risks associated with Vioxx, Celebrex, Bextra and the whole range of NSAIDs drugs. It will soon become the milestone and key document on all future litigation.

The FDA document also provides insight to the amazing conclusions that led to the dramatic undue recall of Bextra and the nonsensical mandatory labeling requirement on all NSAIDs.

Based upon our 25 years of experience in data analysis, especially 'patient longitudinal data', and following a thorough review of what has been published and the FDA's report, Intercon believes that Vioxx, Celebrex and Bextra and other non selective NSAIDs, when prescribed and used as labeled, are an effective pain reliever that are not a direct contributor to heart attacks or stroke.

A white paper, authored by Avi Shatz, the founder, Chairman and CTO of Intercon titled "Politics, Pain and the Torture of the American People" is available for download here:

Politics, Pain and the Torture of the American People

(The document requires Adobe Acrobat Reader)

The 6 page PDF document provides critical analysis and discussion of the FDA's decisions.

About Intercon:

Intercon is a 25-year-old company, specializing in large scale data analysis using large databases. It has many of the major pharmaceutical companies as clients, but not Merck or Pfizer. Intercon's DynaTrack software is becoming the Gold Standard for longitudinal (over time) study of patient data. It analyzes data on millions of patients and billions of scripts (prescriptions) rapidly.

Intercon's web site can be reviewed at Intercon Ltd.


Intercon has not received or been promised any compensation by Merck, Pfizer or any other major participant in the discussed controversy. None of its officers or employees owns any equity or derivatives in those same companies.

For Further Information Contact: Avi Shatz, in Jerusalem, ISRAEL

US toll free: 1 -888-202 9801,
+972.2 653.5496

or by email:

Additional References:

The FDA's Milestone Document

(The document requires Adobe Acrobat Reader)